AU2005310247A1 - Methods for inhibition of NKT cells - Google Patents

Methods for inhibition of NKT cells Download PDF

Info

Publication number
AU2005310247A1
AU2005310247A1 AU2005310247A AU2005310247A AU2005310247A1 AU 2005310247 A1 AU2005310247 A1 AU 2005310247A1 AU 2005310247 A AU2005310247 A AU 2005310247A AU 2005310247 A AU2005310247 A AU 2005310247A AU 2005310247 A1 AU2005310247 A1 AU 2005310247A1
Authority
AU
Australia
Prior art keywords
agent
nkt cell
cells
nkt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2005310247A
Other languages
English (en)
Inventor
Everett Hurteau Meyer
Samuel Strober
Dale T. Umetsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of AU2005310247A1 publication Critical patent/AU2005310247A1/en
Priority to AU2011250800A priority Critical patent/AU2011250800B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2005310247A 2004-11-02 2005-11-02 Methods for inhibition of NKT cells Abandoned AU2005310247A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2011250800A AU2011250800B2 (en) 2004-11-02 2011-11-16 Methods for inhibition of NKT cells

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US60/624,568 2004-11-02
US70654805P 2005-08-08 2005-08-08
US60/706,548 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011250800A Division AU2011250800B2 (en) 2004-11-02 2011-11-16 Methods for inhibition of NKT cells

Publications (1)

Publication Number Publication Date
AU2005310247A1 true AU2005310247A1 (en) 2006-06-08

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005310247A Abandoned AU2005310247A1 (en) 2004-11-02 2005-11-02 Methods for inhibition of NKT cells

Country Status (11)

Country Link
US (2) US7682614B2 (https=)
EP (1) EP1812015B1 (https=)
JP (1) JP4948418B2 (https=)
CN (1) CN101031307B (https=)
AT (1) ATE539757T1 (https=)
AU (1) AU2005310247A1 (https=)
CA (1) CA2584971C (https=)
DK (1) DK1812015T3 (https=)
ES (1) ES2378076T3 (https=)
PT (1) PT1812015E (https=)
WO (1) WO2006060117A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1372668B1 (en) 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
WO2011149881A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Methods for the treatment and prevention of inflammatory diseases
RU2603075C2 (ru) * 2010-11-25 2016-11-20 Имнейт Сарл Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками
US9539281B2 (en) 2011-07-12 2017-01-10 The Brigham And Women's Hospital, Inc. Lipid-containing PSA compositions, methods of isolation and methods of use thereof
JP2015502340A (ja) * 2011-10-27 2015-01-22 エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｉＮＫＴに対するヒト化抗体
EP2906576B1 (en) * 2012-10-12 2019-09-11 The Brigham and Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
AU2013388034B2 (en) 2013-04-30 2019-08-15 Aspeya US Inc. Dry powder formulations and methods of use
US10501541B2 (en) 2015-01-27 2019-12-10 Lava Therapeutics B.V. Single domain antibodies targeting CD1d
JP6918365B2 (ja) 2015-08-19 2021-08-11 プレジデント アンド フェローズ オブ ハーバード カレッジ 脂質化ｐｓａ組成物および方法
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
JP7493449B2 (ja) 2017-09-22 2024-05-31 ヴェクチュラ インコーポレイテッド ステアリン酸マグネシウムを含む乾燥粉末組成物
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
AU2019344300A1 (en) 2018-09-19 2021-04-22 LAVA Therapeutics N.V. Dual acting CD1D immunoglobulin
EP4301374A4 (en) 2021-03-01 2025-09-10 Deciduous Therapeutics Inc COMPOUNDS FOR ACTIVATING INVARIANT NATURAL KILLER T CELLS AND METHODS OF USE IN ELIMINATING INFLAMMATORY SENESCENT CELLS
JPWO2023153527A1 (https=) * 2022-02-14 2023-08-17

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
US5679347A (en) 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
EP0751780B1 (en) 1993-06-21 2003-09-03 Brigham And Women's Hospital Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3495740B2 (ja) 1997-04-10 2004-02-09 麒麟麦酒株式会社 α−グリコシルセラミドを含有するＮＫＴ細胞活性化剤
EP1011719A1 (en) 1997-09-12 2000-06-28 Brigham & Women's Hospital Synthetic antigens for cd1-restricted immune responses
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
EP1095062B1 (en) 1998-07-09 2006-09-13 Brian J. Nickoloff Method of treating disorders by modulating the interaction of natural killer receptors on t cells with their respective ligands
US20010051156A1 (en) 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
US20020071842A1 (en) 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
EP1288291A4 (en) 2000-06-06 2004-05-12 Kirin Brewery METHOD FOR REPLACING NATURAL KILLER T CELLS
JP5184732B2 (ja) * 2000-06-19 2013-04-17 ベス イスラエル デアコネス メディカル センター Ｔ細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
WO2001098317A2 (en) 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
JP3986957B2 (ja) 2000-08-18 2007-10-03 三菱電機株式会社 ランプ用トランス
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
IL140537A0 (en) 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
EP1372668B1 (en) * 2001-03-26 2011-12-07 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US6662434B2 (en) 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US20030064967A1 (en) 2001-04-11 2003-04-03 Jayraz Luchoomun Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
US20020171538A1 (en) 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) 2001-05-18 2002-11-21 Wegener William E. Security electronic system
EP1434859A2 (en) 2001-07-25 2004-07-07 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
US8084020B2 (en) 2002-05-01 2011-12-27 Beth Israel Deaconess Medical Center Use of anti-CD1 antibodies for the modulation of immune responses
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
ES2365210T3 (es) 2002-06-14 2011-09-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health Procedimientos de tratamiento y prevención de colitis en la que se implican la il-13 y los linfocitos t citolíticos naturales.
US7368142B2 (en) 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
WO2004019900A1 (en) 2002-08-27 2004-03-11 Societe Des Produits Nestle Preventing or treating epithelial tissue damage or hair loss
AU2003277021A1 (en) 2002-09-27 2004-04-19 Biomira, Inc. Glycosylceramide analogues
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
WO2005032462A2 (en) 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
AU2003225891A1 (en) 2003-03-20 2004-11-19 Brigham Young University 6"-amino-6"-deoxygalactosylceramides
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
EP1653977A2 (en) 2003-07-17 2006-05-10 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Treatment of disorders associated with natural killer t cells
EP1767216B1 (en) * 2004-06-11 2012-07-11 Riken Drug having regulatory cell ligand contained in liposome

Also Published As

Publication number Publication date
WO2006060117A3 (en) 2007-03-01
JP2008518974A (ja) 2008-06-05
JP4948418B2 (ja) 2012-06-06
ES2378076T3 (es) 2012-04-04
CA2584971C (en) 2013-08-06
WO2006060117A2 (en) 2006-06-08
US7682614B2 (en) 2010-03-23
ATE539757T1 (de) 2012-01-15
CN101031307A (zh) 2007-09-05
CN101031307B (zh) 2012-09-05
US20100197613A1 (en) 2010-08-05
CA2584971A1 (en) 2006-06-08
EP1812015A2 (en) 2007-08-01
EP1812015A4 (en) 2008-02-20
EP1812015B1 (en) 2012-01-04
PT1812015E (pt) 2012-02-20
US20060116332A1 (en) 2006-06-01
DK1812015T3 (en) 2013-01-02
US8679499B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
US8679499B2 (en) Methods for relieving asthma-associated airway hyperresponsiveness
JP6764396B2 (ja) 二糖合成脂質化合物およびその使用
Willis et al. Release and actions of prostaglandins in inflammation and fever: inhibition by anti-inflammatory and antipyretic drugs
US20180105547A1 (en) Methods for the treatment and prevention of inflammatory diseases
JP4804626B2 (ja) 免疫レギュレータ
US20050053612A1 (en) Nucleotide regulation of immune responses
US20210317218A1 (en) Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
Persat et al. Inhibition of human peripheral blood mononuclear cell proliferative response by glycosphingolipids from metacestodes of Echinococcus multilocularis
JP2009520730A (ja) アレルギー性疾患を治療および予防するための手段および方法
AU2011250800B2 (en) Methods for inhibition of NKT cells
US20100204295A1 (en) Treatment of allergic disease with immunomodulator compounds
CA2750607C (en) Composition comprising carbohydrate esters of mycolic acid derivatives_and process for the preparation thereof
WO2016144760A1 (en) Compositions and methods for treating allergic inflammation
Schuyler et al. Immunoglobulin response to intrapulmonary immunization of asthmatics
WO2009135001A2 (en) Methods and compositions for regulating th2 and th17 responses
EP1827488B1 (en) Composition comprising phosphatidyl serine and an antigen or allergen and the use thereof
US20130281409A1 (en) Myelin Sheath Fatty Acids that Resolve Neuroinflammation
US20050277602A1 (en) Methods employing agonists of P38 map kinase for the treatment of asthma
Marti et al. 603 CONSULTATION DUE TO ADVERSE REACTIONS CAUSED BY LOCAL ANESTHETICS IN THE AREA OF BARCELONA

Legal Events

Date Code Title Description
MK24 Application lapsed reg. 22.2e(2) - failure to pay response fee
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE EXAMINATION RESPONSE FEE HAS BEEN EXTENDED TO 02 JUL 2011.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted